Skip to main content
Premium Trial:

Request an Annual Quote

Centogene Regains Compliance With Nasdaq Listing Requirement

NEW YORK — Centogene said on Tuesday that it has been notified by the Nasdaq that its shares have regained compliance with the stock exchange's $1 minimum bid price requirement.

As a result, the stock can continue trading on Nasdaq.

In December, the German molecular diagnostics company said that it received notification of its failure to meet the Nasdaq requirement after its shares failed to close with a bid price of at least $1 for 30 consecutive trading days.

Centogene said that its shares maintained a minimum closing bid price of $1 for at least 10 consecutive trading days earlier this month, putting them back in compliance with the Nasdaq's rule.

During early Tuesday trading, Centogene's stock was down $.04 at $1.39.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.